Contact
searchSearch
HMP Global
Login

Small Cell Lung Cancer Resource Center

News
Palliative Care Needs in Patients With Small Cell Lung Cancer and Caregivers: Survey Insights
10/16/2024
Grace Taylor, MS, MA
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024...
10/16/2024
Journal of Clinical Pathways
Trending From ACCC
Barriers to Treating Patients With Small Cell Lung Cancer: Findings from a Survey of Patients and Providers
06/05/2023
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the...
06/05/2023
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022
Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
Jerome Goldschmidt, MD
Videos
Health Care Resource Utilization, Costs, and Treatment Patterns Among Patients With Extensive-Stage SCLC Treated in the Community Oncology Setting
03/25/2022
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD,...
03/25/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021
Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways
News
Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC
12/03/2021
Marta Rybczynski
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study...
12/03/2021
Journal of Clinical Pathways
Quiz
Quiz: Evolution of Diagnosis and Treatment of SCLC
11/18/2021
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in...
11/18/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Third-Line Nivolumab for SCLC
11/15/2021
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab...
11/15/2021
Journal of Clinical Pathways
News
Evolution of Diagnosis and Treatment of SCLC Over the Last 20 Years
10/22/2021
Marta Rybczynski
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that...
10/22/2021
Journal of Clinical Pathways
David Tsui, MD
Videos
Real-World Adoption and Outcomes of Atezolizumab Plus Carboplatin and Etoposide for Extensive-Stage SCLC
10/04/2021
David Chun Cheong Tsui, MD, discusses results from a real-world study exploring the adoption and early clinical outcomes of atezolizumab plus carboplatin and etoposide in patients with extensive-stage SCLC.
David Chun Cheong Tsui, MD, discusses results from a real-world study exploring the adoption and early clinical outcomes of atezolizumab plus carboplatin and etoposide in patients with extensive-stage SCLC.
David Chun Cheong Tsui, MD,...
10/04/2021
Journal of Clinical Pathways
News
Third-Line Nivolumab Cost-Effective Compared to Topotecan for SCLC
09/07/2021
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that...
09/07/2021
Journal of Clinical Pathways

News Articles

News
Palliative Care Needs in Patients With Small Cell Lung Cancer and Caregivers: Survey Insights
10/16/2024
Grace Taylor, MS, MA
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024...
10/16/2024
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022
Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021
Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways
News
Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC
12/03/2021
Marta Rybczynski
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study...
12/03/2021
Journal of Clinical Pathways
News
Evolution of Diagnosis and Treatment of SCLC Over the Last 20 Years
10/22/2021
Marta Rybczynski
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that...
10/22/2021
Journal of Clinical Pathways
News
Third-Line Nivolumab Cost-Effective Compared to Topotecan for SCLC
09/07/2021
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that...
09/07/2021
Journal of Clinical Pathways
News
Durvalumab Plus Chemotherapy Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
09/01/2021
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest...
09/01/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of First-Line Chemo-Immunotherapy for Extensive-Stage SCLC
08/05/2021
Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...
Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...
Study findings suggest...
08/05/2021
Journal of Clinical Pathways
News
Nivolumab vs Standard of Care for Third-Line Treatment of SCLC
08/04/2021
Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.
Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.
Study findings show third-line...
08/04/2021
Journal of Clinical Pathways
News
Real-World Treatment Patterns and Outcomes Among Patients With SCLC
07/22/2021
A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.
A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.
A recent systematic review on...
07/22/2021
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
EHR-Embedded CDS Tool Enhances Specialty Drug Management in Oncology
03/28/2025
Juliet Gallagher
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference evaluated how embedding a clinical decision support (CDS) tool within the electronic health record (EHR) can enhance specialty drug...
A retrospective study presented...
03/28/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Evolution of Diagnosis and Treatment of SCLC
11/18/2021
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in...
11/18/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Third-Line Nivolumab for SCLC
11/15/2021
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab...
11/15/2021
Journal of Clinical Pathways
Quiz
Quiz: Third-Line Treatment for SCLC
08/30/2021
True or False: Nivolumab is less effective than standard of care for the third-line treatment of SCLC.
True or False: Nivolumab is less effective than standard of care for the third-line treatment of SCLC.
True or False: Nivolumab is less...
08/30/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Prophylactic Cranial Irradiation vs MRI Surveillance for SCLC
07/15/2021
True or False: Prophylactic cranial irradiation is cost-effective compared with MRI surveillance for extensive-stage small cell lung cancer.
True or False: Prophylactic cranial irradiation is cost-effective compared with MRI surveillance for extensive-stage small cell lung cancer.
True or False: Prophylactic...
07/15/2021
Journal of Clinical Pathways
Test Your Knowledge
Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?
08/01/2019
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with...
08/01/2019
Oncology
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Palliative Care Needs in Patients With Small Cell Lung Cancer and Caregivers: Survey Insights
10/16/2024
Grace Taylor, MS, MA
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024...
10/16/2024
Journal of Clinical Pathways
Trending From ACCC
Barriers to Treating Patients With Small Cell Lung Cancer: Findings from a Survey of Patients and Providers
06/05/2023
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the...
06/05/2023
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022
Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
Jerome Goldschmidt, MD
Videos
Health Care Resource Utilization, Costs, and Treatment Patterns Among Patients With Extensive-Stage SCLC Treated in the Community Oncology Setting
03/25/2022
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD,...
03/25/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021
Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use